登录新浪财经APP 搜索【信披】查看更多考评等级 根据港交所上市委员会的决定，今天上午9点，曾经的"早筛第一股"诺辉健康（06606.HK）将正式从港 交所退市。 退市，并不意味着诺辉健康这家公司的终结。 《健闻咨询》独家获悉，诺辉健康大幅裁撤了原销售线，但保留了医学部门，这或许旨在续旧证、申新 证。有内部消息称，诺辉健康的HPV筛查产品"宫证清"已被药监部门拒审，而将于今年11月8日到期 的"早筛第一证"常卫清，仍在续证流程当中。 维权，或许是这个时间点上，关于诺辉健康唯一还有讨论空间的部分。 11月14日，也就是17天后的深夜，诺辉健康寻求清盘令的聆讯将在公司注册所在地的开曼群岛大法院进 行。对于诺辉健康来说，这或许只是其强制退市流程中的固定环节，但对于被"闷杀"的一般股东（即个 人投资者）而言，一旦进入清盘程序，就几乎意味着四个字——"血本无归"。 据了解，4000多名诺辉健康的个人投资者已经形成维权共同体，发起者朱江（此前做空诺辉健康的幕后 人物），聘任了一个8-9人的律师团队，希望在内地、香港双线作战，以尽可能追讨损失。 面对港股中因财报造假而被强制退市的公司，内地投资者该如何维权？ 近日，《健闻咨 ...

Core Viewpoint - The valuation of Nohow Health has been drastically reduced by multiple fund companies, reflecting a pessimistic outlook on its prospects for resuming trading after a prolonged suspension of nearly 15 months [1][2][5]. Valuation Adjustments - On June 25, Changcheng Fund announced a new valuation of Nohow Health at HKD 1.20 per share, representing a 91.51% decrease from its last trading price of HKD 14.14 per share [3][5]. - Since mid-last year, over 40 valuation adjustments have been made by various fund companies, with Dachen Fund adjusting its valuation from HKD 10.12 per share to HKD 1.81 per share [7]. Company Background - Nohow Health, once known as "China's first cancer screening stock," was listed on the Hong Kong Stock Exchange in February 2021 and focuses on the development and commercialization of screening products for colorectal, gastric, and cervical cancers [8]. - The company faced serious allegations of financial misconduct, including a report by Capital Watch claiming that its actual sales for 2022 were only CNY 76.95 million, significantly lower than the reported CNY 765 million [8]. Regulatory and Management Issues - Deloitte raised three major concerns regarding Nohow Health's 2023 annual report, questioning the validity of sales transactions and the effectiveness of marketing expenditures [8]. - Nohow Health was suspended from trading on March 28, 2024, due to its inability to publish its annual report on time, and its founder resigned from key positions in December 2024 [8]. Potential Delisting - According to Hong Kong Stock Exchange regulations, if Nohow Health remains suspended for 18 months, it may face mandatory delisting, with only about three months left before this deadline [9].

Core Viewpoint - The valuation of Nohui Health has been drastically reduced by multiple fund companies, reflecting a pessimistic outlook on its prospects for resuming trading after a prolonged suspension [2][4][9]. Valuation Adjustments - On June 25, Changcheng Fund announced a new valuation of Nohui Health at 1.20 HKD per share, a 91.51% decrease from its last trading price of 14.14 HKD [7][12]. - Since mid-last year, over 40 valuation adjustments have been made by various fund companies, with Dachen Fund reducing its valuation from 10.12 HKD to 1.81 HKD [9][11]. - Shanghai Guangzheng Asset Management has also adjusted its valuation four times, from 12.73 HKD to 5.70 HKD [9]. Company Background - Nohui Health, once known as "China's first cancer screening stock," was listed on the Hong Kong Stock Exchange in February 2021 and focuses on the development and commercialization of screening products for colorectal, gastric, and cervical cancers [11]. - The company faced allegations of financial misconduct, with a report claiming its actual sales in 2022 were only 76.95 million, significantly lower than the reported 765 million [11]. Suspension and Future Risks - Nohui Health has been suspended from trading since March 28, 2024, due to its inability to publish its annual report on time [12]. - According to Hong Kong Stock Exchange regulations, if the suspension lasts for 18 months, the company may face mandatory delisting, leaving it with approximately three months before this deadline [13].